ANY004X

ANY004X is an oral peptide candidate currently in preclinical development by Anya Biopharm. The drug is engineered using the proprietary Mira/Je® oral peptide delivery platform, which enhances the oral bioavailability of peptides through a specialized formulation involving metal ions, reducing agents, and permeation enhancers. While Anya Biopharm's pipeline includes specific candidates for metabolic and inflammatory diseases (such as GLP-1 receptor agonists and TNFR inhibitors), the exact therapeutic target and indication for ANY004X remain undisclosed. The company has designated the asset as available for strategic collaboration and partnership.